The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Surprised not to see any posts today on the falling SP which is down 19% today as I type following the falls last week. Am I the only one concerned?
Why the sudden drop?
I'm new to this share . Revenue of £429k and a loss of £7.2m. Why would anyone invest here? Serious question. Not having a dig as I say I don't know the background and I'm sure I'm missing something. Would be grateful if someone could enlighten me. Thanks
If my maths is correct $17.6M cash balance as at 31/10/17 according to today's RNS and 27.78M shares in issue equates to a value of $0.63 per share. This is before liquidation costs of course.
Silver Falcon Plc (the "Company") Proposed acquisition of Hemogenyx LLC Change of Name to Hemogenyx Pharmaceuticals Plc Placing & Subscription to raise £2m Readmission to the Official List on 5 October 2017 Silver Falcon Plc (LSE: SILF) announces the agreement to acquire Hemogenyx Pharmaceuticals Limited for £8m (the "Acquisition") to be satisfied by the issue of 228,571,428 Consideration Shares at a price of 3.5p per share. Hemogenyx Pharmaceuticals Limited is the holding company for Hemogenyx LLC ("Hemogenyx"), a US based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation. In conjunction with the Acquisition, the Company has raised £2m through the issue of 57,142,857 New Ordinary Shares in a Placing and Subscription at a price of 3.5p per share, plus 1 for 2 warrants to qualifying shareholders over 62,021,429 New Ordinary Shares at 4.0p per share. Optiva Securities Ltd, Shard Capital Partners LLP and Peterhouse Corporate Finance Limited, acted as agents for the Company. In addition, 3,428,541 New Ordinary Shares will be issued to directors and advisers and up to 24,566,952 New Ordinary Shares will be available under options granted or to be granted to employees, proposed directors and advisory board members. As the Acquisition is classified as a reverse takeover for the purpose of the Listing Rules, completion of the Acquisition, together with the Placing and Subscription will require the cancellation of the Existing Ordinary Shares on the standard listing segment of the Official List and readmission of the Existing Ordinary Shares and the admission of the New Ordinary Shares to the standard listing segment of the Official List maintained by the FCA and to trading on the main market for listed securities of the London Stock Exchange. Completion of the Acquisition, Placing and Subscription is conditional upon the Resolutions being passed at the General Meeting of the Company, to be held at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD at 10.00 a.m. on 4 October 2017. Subject to passing of the Resolutions, it is expected that Admission will become effective, and that dealings in the Ordinary Shares will commence at 8.00 a.m. on 5 October 2017. The Company will then trade under the new company name of Hemogenyx Pharmaceuticals Plc and new ticker symbol "HEMO". The market capitalisation of the Company is expected to be £12.46m on Admission. HIGHLIGHTS · Hemogenyx is a preclinical stage biopharmaceuti
Proposed acquisition and placing. At last!!
Spoke to the NOMAD, Allenby Capital, this morning. Couldn't tell me much when I asked how much longer the distribution would take to be finalised as this is price sensitive information. All they would say is these things take time, it is being worked on and an announcement would be made in due course.
A few sellers getting impatient waiting for news on the distribution which is understandable. Have tried contacting a couple of the directors in Dubai to get an update but they are never available. Very frustrating!
When everyone is selling is the time to be buying. Isn't that what they say! Could be right in this case.
Surely it can't be long now before we get details and timing of the distribution???
Master Services Agreement signed with one of the worlds largest market research companies. Potentially transformational according to our CEO. Great news.
My guess is they will return all to shareholders (less admin costs and any taxes dues). We should find out soon.
Anyone know the procedure for distributing cash to shareholders? Hope it will be a speedy process and that Tejoori have arrangements more of less in place knowing the final plot sale was a done deal since the MOU.